NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

PTC Therapeutics, Inc. (PTCT) Stock Analysis

PTC Therapeutics, Inc. (PTCT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PTCT

$69.30

−$2.10 (−2.94%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PTCT with… →

PTCT Key Statistics

As of Sep 4, 2026
Trading
Open
$70.62
Previous Close
$71.40
Day's Range
69.26–71.41
52-Week Range
56.51–90.87
Volume
673.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.55
Valuation
Market Cap
$5.78B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
27.72
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.65
Financials (FY)
Revenue (FY)
$1.73B+114.51%
Net Income (FY)
$682.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.81%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
83.46M
1-Year Return
+19.46%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.65M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PTCT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.77%
2025+68.28%
2024+63.79%
2023−27.80%
2022−4.17%
2021−34.74%
2020+27.07%
2019+39.95%
2018+105.76%
2017+52.89%
2016 (partial year)+43.55%

As of September 4, 2026.

PTCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.73B$682.64M39.4%
2024$806.78M−$363.30M−45.0%
2023$937.82M−$626.60M−66.8%
2022$698.80M−$559.02M−80.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.73B$1.68B$856.51M$682.64M39.4%
2024$806.78M$749.38M−$146.75M−$363.30M−45.0%
2023$937.82M$872.34M−$349.40M−$626.60M−66.8%
2022$698.80M$654.12M−$439.93M−$559.02M−80.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PTCT Valuation vs Biotechnology Median

Median of 656 stocks
MetricPTCTBiotechnology medianvs median
P/S ratio5.7315.2662% below
Profit margin−3.81%0.00%3.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values PTC Therapeutics, Inc. (PTCT) at $5.78B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 991.

The 52-week range on file runs from $56.51 to $90.87. The most recent close on file for PTCT is $69.30, dated September 4, 2026. That is −$2.10 (−2.94%) against the previous close. The latest close sits 22.64% above that 52-week low.

Financial Health

In fiscal 2025, PTC Therapeutics, Inc. reported revenue of $1.73B. That is +114.51% against the prior fiscal year, when revenue was $806.78M. Net income for the same year was $682.64M. Profit margin runs at −3.81%. That is 3.8 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.65.

Across the 4 fiscal years on file, revenue moves from $698.80M in 2022 to $1.73B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 27.72. Measured against sales, the shares trade at 5.73 times revenue. On price-to-sales that is 62.44% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +19.46%. Across 10 years the annualized return works out at +24.24%. The reported beta is 0.55. Annualized volatility over the trailing 10 years is 65.53%.

Growth & Income

No dividend is on file for PTCT.

2026 is still running; the price is −8.77% year to date. Across the complete calendar years on file, 2018 returned +105.76% and 2021 returned −34.74%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

PTC Therapeutics, Inc. (PTCT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PTC Therapeutics, Inc. PTCT $5.78B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. PTC Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Visit website →